A Histological Assessment Tool for Breast Implant Capsules Validated in 480 Patients with and without Capsular Contracture - Larsen, Andreas; Timmermann, Adam M; Kring, Mikela; Weltz, Tim K; Ørholt, Mathias; Vester-Glowinski, Peter; Elberg, Jens Jørgen; Trillingsgaard, Jesper; Mielke, Louise V; Hölmich, Lisbet R; Damsgaard, Tine E; Roslind, Anne; et al. (medRxiv, 2023)
Background Capsular contracture is a severe complication to breast implants, but the pathophysiology remains unclear, and consensus is lacking on how to analyze implant capsules histologically. In this study, we developed and validated a histological semiquantitative assessment tool for analyzing breast implant capsules.Methods Biopsies of breast implant capsules from 480 patients who had undergone breast augmentation or reconstruction were collected and stained with hematoxylin and eosin. First, biopsies from 100 patients were used to select parameters for the semiquantitative assessment tool. Then, biopsies from the remaining 380 patients were used to determine intra- and interobserver agreement of two blinded observers and agreement with a pathologist. Finally, we tested the association between the parameters and capsular contracture.Results The histological assessment tool consisted of ten parameters assessed on a two-, three-, or four-point scale. Intra- and interobserver agreement was almost perfect (0.83 and 0.80), and agreement with the pathologist was substantial (0.67). Inflammatory infiltration (p<0.01), thickness of the collagen layer (p<0.0001), fiber organization (p<0.01) and calcification (p<0.001) were significantly correlated with capsular contracture.Conclusions This is the first validated histological assessment tool for breast implant capsules that provides an objective and precise assessment of hematoxylin and eosin-stained sections of breast implant capsule biopsies which can be used in research and clinical practice.Level of evidence No Level AssignedCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Research Fund of Rigshospitalet and the Novo Nordisk Foundation (grant number 052198)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Regional Ethics Committee (H-20015276) and the Danish Data Protection Agency (P-2020-176 and P-2020-177).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors